<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119738</url>
  </required_header>
  <id_info>
    <org_study_id>210410004</org_study_id>
    <nct_id>NCT05119738</nct_id>
  </id_info>
  <brief_title>Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment</brief_title>
  <official_title>Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally.&#xD;
      Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy&#xD;
      have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the&#xD;
      BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning &gt;94% efficacy&#xD;
      against COVID-19. However, global access has not been equitable, with many low- and&#xD;
      middle-income countries having no vaccine access or access under emergency use mainly to&#xD;
      traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing),&#xD;
      CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower&#xD;
      concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after a&#xD;
      mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in&#xD;
      immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19.&#xD;
      As such several countries including United States, Israel and Chile have recommended a third&#xD;
      vaccine dose for this vulnerable population.&#xD;
&#xD;
      In this observational study we will explore the humoral response to the BNT162b2 vaccine in&#xD;
      patients who received two previous doses of the inactivated vaccine Coronavac or two doses of&#xD;
      BNT162b2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of positive neutralizing antibodies 8 to 12 weeks after third dose BNT162b2 (booster vaccine).</measure>
    <time_frame>8 to12 weeks after third dose BNT162b2.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing geometric mean titers 8 to 12 weeks after third dose BNT162b2 (booster vaccine)</measure>
    <time_frame>8 to12 weeks after third dose BNT162b2.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Sars-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Three doses of BNT162b2.</arm_group_label>
    <description>Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two doses of Coronavac and one of BNT162b2.</arm_group_label>
    <description>Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of BNT162b2 (observational)</intervention_name>
    <description>BNT162b2 (COVID 19 mRNA vaccine)</description>
    <arm_group_label>Three doses of BNT162b2.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of Coronavac and one dose BNT162b2 (observational)</intervention_name>
    <description>BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)</description>
    <arm_group_label>Two doses of Coronavac and one of BNT162b2.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients receiving their care at the Red de Salud UC Christus in Santiago Chile will&#xD;
        be invited&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Vaccination with two doses of Coronavac vaccine or BNT162b2 vaccine&#xD;
&#xD;
          -  Eastern Cooperative Oncology group performance status &lt; 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous SARS-CoV-2 infection&#xD;
&#xD;
          -  Vaccination with booster vaccine more than 12 weeks before informed consent&#xD;
&#xD;
          -  Intravenous inmunoglobulin therapy 60 days before informed consent&#xD;
&#xD;
          -  Any condition that could interfere with the paticipantÂ´s participation during the&#xD;
             study in the opinion of the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno Nervi</last_name>
    <phone>9978073559</phone>
    <email>bnervi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Red de Salud UC Christus</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Nervi</last_name>
      <phone>+56978073559</phone>
      <email>bnervi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

